2018 ENERGY AND CHEMICALS ANTITRUST REPORT

| January 7, 2019

article image
Produced by the firm’s nationally recognized antitrust practice, the Vinson & Elkins Energy and Chemicals Antitrust Report provides a comprehensive analysis of antitrust developments specific to the energy and chemical industries. The Report also provides merger enforcement data over the last decade-specific to these industries.

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

OTHER ARTICLES

CHEMICAL SPILL PREVENTION

Article | February 28, 2020

When it comes to your workplace, nothing should be prioritized over the safety of your employees. As your greatest asset to your business, they should feel safe in their work environment. Maintaining a safe work environment is a particularly important consideration for companies who work with or store hazardous materials. And it is not only critical for the appeasement of the Occupational Health and Safety Administration (OSHA) and the Environmental Protection Agency (EPA) requirements but the well-being and safety of your employees. That’s why, in this article, we will discuss chemical spill prevention in your workplace facility.

Read More

Guyana-Suriname basin: Rise from obscurity to super potential

Article | May 13, 2021

Recent discoveries in the Guyana-Suriname basin attest to estimates of 10+ Bbbl of oil resources and more than 30 Tcf of gas.1 Like many oil & gas successes, this is a story that begins with early exploration success onshore, followed by a long period of exploration disappointment in coastal to shelf regions offshore, eventually culminating in deepwater success.

Read More

Coronavirus Impact on Fine Chemical Supply Chain

Article | March 6, 2020

Coronavirus, more accurately referred to as COVID-19, is beginning to impact global supply chains in a tangible way. Although it is impossible to forecast the effect of numerous epidemics worldwide on the fine chemical supply chain specifically, reports suggest that as much as 94% of the Fortune 1000 are already experiencing coronavirus-related supply disruptions. Fortune cites the devastating 2011 tsunami as a case study of how unforeseeable disasters can severely disturb supply chains with far-reaching ramifications. Damage to Mitsubishi Gas Chemical factories in the area affected by the tsunami led to a shortage of bismaleimide triazine (BT) resin; a critical material for electronic substrates.

Read More

What is Rate of Reaction and Why is It Important For The Chemical Industry?

Article | February 18, 2020

It would not be an exaggeration to say that the rate of reaction is the true lifeline of the chemical industry in India, and the whole world. A lower rate of reaction would mean, chemical manufacturers can produce products at much faster rates which gives them a great competitive advantage over others. The chemical industry strives to create a faster rate of reactions as it impacts revenue goals.

Read More

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Events